Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Completed · Phase 2

Conditions studied: Carcinoma, Renal Cell

In brief

In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.

Key facts

Study ID

NCT00044564

Run by

Bayer

People needed

54

Starts

2001-12-01

Expected to finish

2003-01-01

Last updated by the study team

2014-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — La Jolla, California, United States
• Study site — Muncie, Indiana, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Greenbelt, Maryland, United States
• Study site — Detroit, Michigan, United States
• Study site — Southfield, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Billings, Montana, United States
• Study site — New Brunswick, New Jersey, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Calgary, Alberta, Canada
• Study site — Edmonton, Alberta, Canada
• Study site — Greater Sudbury, Ontario, Canada
• Study site — Caen, France
• Study site — Montpellier, France
• Study site — Heidelberg, Baden-Wurttemberg, Germany
• Study site — Tübingen, Baden-Wurttemberg, Germany
• Study site — München, Bavaria, Germany
• Study site — München, Bavaria, Germany
• Study site — Düsseldorf, North Rhine-Westphalia, Germany
• Study site — Münster, North Rhine-Westphalia, Germany
• Study site — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.